However, recent studies in patients with normal to minimally elevated ALT levels suggest that this may be too conservative of a recommendation, since patients may still be at risk for liver-related sequelae from CHB.[16] There has been no study to date assessing the effect of antiviral therapy on HCC risk in patients with normal or minimally elevated ALT level but elevated HBV DNA levels.[17,18]. Here, GPT is linked to hepatocellular carcinoma.